Jobs
-
AuraVax Therapeutics announced that the US Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA) has awarded the company a preclinical research contract to support evaluation of AuraVax’s NanoSTING-002 mucosal adjuvant… Read more . . .
-
French vaccine developer Vaxinano announced that it has raised €6 million to support clinical development of several intranasal vaccine candidates based on the Stellar-NP nanoparticle platform. The company’s pipeline includes nasal vaccines against zoonotic diseases… Read more . . .
-
Agomab Therapeutics said that it has closed an $89 million Series D financing round that will support development of several candidates, including its AGMB-447 inhaled ALK5 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF).… Read more . . .
-
Orexo announces the initiation of the OX640-002 trial of OX640 epinephrine nasal powder in people with allergic rhinitis, with results expected in early 2025. The new trial is expected to enroll 30 people with allergic… Read more . . .
-
Intranasal epinephrine developer Bryn Pharma announced that former Aerami Therapeutics Chief Operating Officer Joshua Ziel has joined the company as CEO, succeeding Sandy Loreaux. Prior to joining Aerami in 2022, Ziel held management positions at… Read more . . .
-
The annual Drug Delivery to the Lungs (DDL) conference will mark its 35th anniversary during this year’s meeting, which will take place December 11-13 at the Edinburgh International Conference Centre (EICC). Organizers have set a… Read more . . .
-
Inhaled drug developer Transpire Bio has announced the hires of Timothy Lutz as VP of Manufacturing and Operations; Stuart Loesch as Chief Commercial Officer; and Todd Sunstrom as Head of Quality Assurance. The company recently… Read more . . .
-
Honeywell announced that it has signed a long-term supply agreement with DevPro Biopharma related to the use of Honeywell’s Solstice Air HFO-1234ze in DevPro’s DP007 albuterol metered dose inhaler. Earlier this year, DevPro and CDMO… Read more . . .
-
A striking feature of recent batches of OINDP product specific guidances (PSGs) is the inclusion of strategies for the demonstration of bioequivalence (BE) that eliminate the need for a clinical endpoint trial. Copley Applications Specialist… Read more . . .
-
Aptar Pharma announced that it has acquired nasal delivery technology from Israeli nasal drug developer SipNose Nasal Delivery Systems. In addition to developing devices, SipNose has a pipeline of candidates developed in-house and candidates in… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland